Sarit Assouline - Concepedia

Author

Sarit Assouline

Also Known As

Annie Roy, Assouline, Sarit, L Ardouin, S Assouline, S E Assouline, S. Assouline, S. E. Assouline, S.E. Assouline, Sarit Assouline, Sarit E Assouline

317

Publications

11.1K

Citations

H-Index

Concepts

All Affiliations

Jewish General Hospital McGill University Princess Margaret Cancer Centre The University of Texas MD Anderson Cancer Center Washington University in St. Louis

About

Sarit Assouline is an author at Jewish General Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	37	2.8K
2	Health Sciences	13	16	916
3	Cell Biology	2	2	25
4	Diagnostic Sciences	2	2	34
5	Biostatistics	1	1	123

Sarit Assouline

119

Publications

10K

Citations

H-Index

Page 1

	Year	Citations
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, New England Journal of Medicine	2018	881
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Journal of Clinical Oncology	2019	741
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib Carlo Gambacorti‐Passerini, Laura Antolini, François‐Xavier Mahon, JNCI Journal of the National Cancer Institute	2011	424
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, The Lancet Oncology Lymphoid NeoplasiaBispecific AntibodyMedicineImmunologyImmune Checkpoint Inhibitor	2022	390
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study Stephen M. Ansell, Monique C. Minnema, Peter Johnson, Journal of Clinical Oncology	2019	357
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia Michael Andreeff, Kevin R. Kelly, Karen Yee, Clinical Cancer Research	2015	344
Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles, The Lancet Oncology Lymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunologyImmune Regulation	2015	326
Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin Sarit Assouline, Biljana Čuljković, Eftihia Cocolakis, Blood	2009	306
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, Journal of Clinical Oncology	2018	305
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma M. Dreyling, Franck Morschhauser, Krimo Bouabdallah, Annals of Oncology	2017	267

Page 1